Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV

AIDS Patient Care STDS. 2014 Oct;28(10):513-6. doi: 10.1089/apc.2014.0149. Epub 2014 Aug 5.

Authors

Nimish Patel¹, Michael Veve, Mona Nasiri, Steven Bliss, Louise-Anne McNutt, Victoria Lazariu, Christopher Miller

Affiliation

¹ 1 Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , Albany, New York.

No abstract available

Publication types

Letter

MeSH terms

Adult
Coinfection
Cross-Sectional Studies
Drug Interactions*
Female
HIV Infections / drug therapy*
Hepatitis C / drug therapy*
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
New York
Probability
Proline / analogs & derivatives*
Proline / therapeutic use
Protease Inhibitors / therapeutic use*
Treatment Outcome

Substances

Protease Inhibitors
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Proline